Sevelamer Carbonate Powder, For Suspension
Product Images NDC 65862-931

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 65862-931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3. Percentage Of Patients (y-axis) Attaining A Phosphorus Reduction From Baseline (mg/dl) At Least As Great As The Value Of The X-axis. (Sevelamer Fig1)

A forest plot displaying the least squares mean difference and 95% confidence intervals comparing Sevelamer Carbonate to placebo across various subgroups. The x-axis shows effect size favoring either Sevelamer Carbonate or placebo. Subgroups include Screening BSA, Baseline Serum Phosphorus, Age, and Dialysis status, with sample sizes and confidence intervals indicated for each.*

FDA Label Image

Figure 4. Mean Phosphorus Change From Baseline For Patients Who Completed 52 Weeks Of Treatment (Sevelamer Fig2)

A line graph showing the percentage of patients with at least a 2x reduction in serum phosphorus (mg/dL) plotted against the reduction from baseline in serum phosphorus. It compares results between Sevelamer Hydrochloride and an active control.*

FDA Label Image

Package Label-principal Display Panel (0.8 g Pouch Carton)

A line graph showing the change in phosphorus levels from baseline over 52 study weeks. Two treatments are compared: Sevelamer Hydrochloride and an Active-Control, with phosphorus change on the vertical axis and study weeks on the horizontal axis. The graph indicates trends in phosphorus reduction over time.*

FDA Label Image

Package Label-principal Display Panel (2.4 g Pouch Carton)

Packaging label for SEVELAMER CARBONATE For Oral Suspension, 0.8 g pouches, orange flavor. The label states it contains 90 pouches and is for oral use. It is distributed by Aurobindo Pharma USA, Inc. and made in India by Aurobindo Pharma Limited. Directions for use and storage conditions are included.*

FDA Label Image

Sevelamer Fig5

The packaging label for Sevelamer Carbonate For Oral Suspension 2.4 g pouches in orange flavor. The label indicates it contains 90 pouches and is labeled for prescription use only. The labeler is Aurobindo Pharma Limited, with distribution by Aurobindo Pharma USA, Inc. Directions and ingredient information are printed, including storage instructions. The NDC number 65862-931-90 is shown along with a barcode.*

FDA Label Image

Chemical Structure (Sevelamer Str)

Chemical structure diagram of Sevelamer Carbonate polymer, showing primary amine groups, crosslinking groups, and polymer network indicated by repeated units and polymer notation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.